President Donald Trump's recent announcement of a 100% tariff on imported branded and patented pharmaceutical products from October 1, 2025, has sent shockwaves through the world pharma industry. While the initiative is designed to favour indigenous U.S. manufacture and cut back on foreign dependence of pharma products, its prospects for India—particularly the almost 3,000 MSMEs driving India's pharma industry—need closer examination.

What's in Trump's Pharma Tariff Mandate?

• All branded and patented drug imports to the U.S will be hit with a 100% import duty, except when the manufacturer is constructing a plant in America.

• Only those products of companies with a U.S. plant in the works will be excluded.

• In the meantime, Indian dominance in generics puts its biggest exports—cheap non-branded medicines—beyond the tariff's reach.

Immediate Impact on Indian Pharma MSMEs

• MSMEs form the backbone of India's generic drug exports, and generic drugs account for almost 85-90% of overall Indian pharma exports to the US.

• As the tariffs affect only patented/branded products, most MSMEs are not impacted in the near term.

• The announcement had created uncertainty in the marketplace, leading to a short-term decline in Indian pharma stocks and investor anxiety regarding potential future tariff extensions to generics and biosimilars.

Key Indian MSME Challenges

• Tariff Escalation in the Future: Since the U.S. is already probing whether generic imports pose a threat to national security, the possibility of tariffs extending to generics cannot be eliminated.

• Sentimental Market Response: Investors globally have become cautious, and there has been a fall of up to 7% for various stocks in response to possible escalation.

• US Market Dependence: The U.S. imports more than one-third of India's pharma exports, valued at approximately $10 billion in FY25, thereby even indirect implications might put MSMEs dependent on contract manufacturing by large exporters under strain.

• Lying" Under Branded: A few MSMEs that produce value-added or specialty generics might find themselves trapped in definitional uncertainties if the U.S. broadens the tariff net.

• Pressure to Localize: MSMEs acting as vendors to Indian big pharma companies might experience pressure to support "Make in America" initiatives—establishing manufacturing, setting up JVs, or investing in the U.S. to remain competitive.

New Opportunities Emerging

• US Manufacturing Entry: Indian companies with U.S. operations—e.g., Cipla, Dr Reddy's, and Lupin—are already compliant. MSMEs may gain as partners or suppliers in such expansion plans, providing bulk actives, components, or processes.

• Value Chain Upgradation: Technical MSMEs can upgrade the value chain—complex generics and biosimilars continue to be in demand and, with strategic regulatory management and/or presence in the U.S., can become drivers of growth.

• Emerging Markets: Firms can gain speed in entering new geographies and diversifying export markets and aim at the EU, Africa, and Latin America, thereby decreasing dependence on the U.S. market.

• Increased Domestic Demand: Domestic pharma demand still grows; MSMEs can switch to serve India's increasing chronic disease and specialty medicine markets.

• Contract Manufacturing and Niche Exports: MSMEs can consolidate contract manufacturing for companies with U.S. facilities or become expert niche exporters of non-tariff exempt items—APIs (active pharma ingredients) and non-patented drugs.

Policy and Trade Outlook

• The Indian government is watching closely, with ministries evaluating near-term and long-term risks and planning further talks.

• Trade associations urge caution and suggest MSMEs remain nimble, invest in compliance, and watch regulatory trends closely.

• The imperative for a fast-tracked India-U.S. or India-EU trade agreement is building to safeguard MSME interests and provide ongoing access to global markets.

Conclusion

Trump's 100% pharma tariffs primarily strike at multinational big pharma but send a significant signal to Indian MSMEs: learn, diversify, and globalize strategically. While short-term pain is contained for generics-oriented MSMEs, futureproofing via innovation, market dexterity, and global collaborations will be essential. The history of Indian pharma's success has always been one of grit and reinvention; these new trade headwinds could just trigger its next phase of transformation.

Industry Bodies & Experts Opinion

• "Because the 100% tariff is focused on branded/patented medicines, the vast majority of Indian generic exports would not be adversely impacted in the near term, although the threat will hang over."  Ajay Sahai, Director General, Federation of Indian Export Organisations

• "The social media release of POTUS mentions patented/branded products exported to the US. It does not apply to generic drugs." Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance

• "India being a generic drug exporter is not likely to be affected at all. But the declaration could have an emotional effect on pharma shares. There is also a possibility that future tariff actions could be extended to generic drugs, which would have a greater effect." Dr. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited

• "Until there is greater clarity on how these tariffs would be imposed, the medium-term outlook for Indian pharma is neutral." Kranthi Bathini, Director of Equity Strategy, WealthMills Securities

• "Making investments in new facilities in the US might not be feasible for generic drug makers, which have wafer thin margins." Industry Expert, Economic Times